ArticleAntimicrobial agents and chemotherapy2019
Antecedent Carbapenem Exposure as a Risk Factor for Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae and Carbapenemase-Producing Enterobacteriaceae.
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Central nervous system infections caused by carbapenem-resistant klebsiella pneumoniae after CAR T-cell therapy in a patient with preexisting colonization: a case report and literature review.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Pooled it
- Carbapenem-resistant Enterobacterales (CRE) acquisition and molecular characterization following colistin monotherapy and colistin-meropenem combination therapy: findings from the AIDA randomized trial.Antimicrobial resistance and infection control · 2025Trial
- Longitudinal trends in community-onset bacteraemia caused by ceftriaxone non-susceptibleJAC-antimicrobial resistance · 2026Article
- Scarless excision of an insertion sequence in the OmpK36 promoter restores meropenem susceptibility in a non-carbapenemase-producingEmerging microbes & infections · 2025Article
- Surveillance and characterization of carbapenem-resistant Enterobacter cloacae complex from China, 2015-2018.BMC microbiology · 2025Article
- Assessment of Factors Contributing to Multidrug Resistance in Urinary Tract Infections: Focus on Carbapenem Resistance.Antibiotics (Basel, Switzerland) · 2025Article
- Cefepime Versus Carbapenem Therapy for the Treatment of Invasive Infections With Inducible Chromosomal AmpC-Producing Enterobacterales: A Systematic Review and Meta-analysis.Open forum infectious diseases · 2025Article
- [Epidemiological characteristics of patients with carbapenemase-producing NDM Enterobacterales isolates in a high-complexity hospital].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025Article
- Risk Factors for Non-Carbapenemase-Producing Carbapenem-ResistantGeriatrics (Basel, Switzerland) · 2025Article
- Risk factors for Carbapenem-resistant Enterobacterales infections: A case-control study.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2025Article
- Risk factors for bloodstream infections due to carbapenem-resistant Enterobacterales: a nested case-control-control study.The Journal of antimicrobial chemotherapy · 2024Article
- Investigation on the mechanisms of carbapenem resistance among the non-carbapenemase-producing carbapenem-resistantFrontiers in cellular and infection microbiology · 2024Article
- Risk factors for carbapenem-resistantJournal of preventive medicine and hygiene · 2023Article
- Carbapenem resistance in Enterobacterales bloodstream infections among children with cancer or post-haematopoietic stem cell transplant: a retrospective cohort study.The Journal of antimicrobial chemotherapy · 2023Article
- The Prevalence of Carbapenemase-Producing Microorganisms and Use of Novel Cephalosporins for the Treatment of Severe Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria in a Pediatric Cardiac Intensive Care Unit.Antibiotics (Basel, Switzerland) · 2023Article
- Meropenem-Vaborbactam Activity against U.S. Multidrug-ResistantMicrobiology spectrum · 2023Article
- Characterisation of Non-Carbapenemase-Producing Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Article
- Activity of meropenem/vaborbactam and comparators against non-carbapenemase-producing carbapenem-resistant Enterobacterales isolates from Europe.JAC-antimicrobial resistance · 2022Article
- Whole-Genome Characterisation of ESBL-ProducingAntibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 12 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.